GlassScriptPhysician profile
Hernan Giraldo
NPI 1740278506
$9,337.47
in general payments reported to CMS, 2019-2025
25 companies · $2,162 in 2025
The $2,162 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $901 · 2021: $1,042 · 2022: $967 · 2023: $1,489 · 2024: $1,682 · 2025: $2,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,452 · Consulting Fee: $750 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,451.75 |
| Consulting Fee | $750.00 |
| Education | $130.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,518.17 | 2019-2025 | Nucala, Trelegy Ellipta |
| Jazz Pharmaceuticals INC. | $2,148.52 | 2019-2025 | Xywav |
| Astrazeneca Pharmaceuticals LP | $1,895.61 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $499.81 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $469.22 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.23 | 2019-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $277.63 | 2019-2025 | Dupixent |
| Avadel Cns Pharmaceuticals, LLC | $200.00 | 2025 | Lumryz |
| Actelion Pharmaceuticals US, INC. | $184.23 | 2019-2025 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $182.06 | 2020-2023 | Yupelri |
| Amgen INC. | $152.96 | 2023-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $68.19 | 2019 | |
| Merck Sharp & Dohme LLC | $61.82 | 2021-2025 | Winrevair |
| Insmed, INC. | $49.81 | 2019-2021 | |
| Grifols USA, LLC | $49.54 | 2023 | Prolastin-C Liquid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $44.57 | 2025 | |
| Mallinckrodt Hospital Products INC. | $38.76 | 2023 | Acthar |
| Csl Behring | $33.64 | 2019 | |
| Axsome Therapeutics, INC. | $33.57 | 2023 | Sunosi |
| Pfizer INC. | $30.14 | 2023 | |
| Paratek Pharmaceuticals, INC. | $23.81 | 2024 | Nuzyra |
| Shionogi INC | $20.27 | 2022 | |
| 3b Medical, INC. | $18.19 | 2024 | Luna |
| Idorsia Pharmaceuticals US INC | $13.95 | 2023 | Quviviq |
| Lilly USA, LLC | $13.77 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hernan Giraldo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.